|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 100.30 USD | +1.30% |
|
+0.58% | +0.82% |
| Capitalization | 249B 212B 198B 186B 343B 22,548B 375B 2,312B 897B 10,629B 934B 914B 38,778B | P/E ratio 2025 * |
13x | P/E ratio 2026 * | 14.5x |
|---|---|---|---|---|---|
| Enterprise value | 274B 234B 218B 205B 378B 24,843B 413B 2,548B 988B 11,711B 1,029B 1,007B 42,725B | EV / Sales 2025 * |
4.23x | EV / Sales 2026 * | 3.92x |
| Free-Float |
70.67% | Yield 2025 * |
3.22% | Yield 2026 * | 3.26% |
Last Transcript: Merck & Co., Inc.
| 1 day | +1.30% | ||
| 1 week | +0.58% | ||
| Current month | -4.32% | ||
| 1 month | +7.93% | ||
| 3 months | +21.12% | ||
| 6 months | +22.75% | ||
| Current year | +0.82% |
| 1 week | 96.06 |  | 100.66 |
| 1 month | 92.11 | | 105.84 |
| Current year | 73.31 | | 105.84 |
| 1 year | 73.31 | | 105.84 |
| 3 years | 73.31 | | 134.63 |
| 5 years | 70.89 | | 134.63 |
| 10 years | 47.97 | | 134.63 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Davis
CEO | Chief Executive Officer | 58 | 2021-06-30 |
| Director of Finance/CFO | 56 | 2021-03-31 | |
Dave Williams
CTO | Chief Tech/Sci/R&D Officer | 56 | 2020-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Tom Glocer
BRD | Director/Board Member | 65 | 2007-11-26 |
Patricia Russo
BRD | Director/Board Member | 72 | 1995-08-31 |
Robert Davis
CHM | Chairman | 58 | 2022-11-30 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 14.34% | 303 M€ | -21.05% | - |
| 5.61% | 26 M€ | +12.27% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.30% | +0.58% | -1.67% | -9.57% | 249B | |
| +1.80% | +1.70% | +30.21% | +186.49% | 920B | |
| +0.75% | +4.78% | +44.31% | +18.06% | 510B | |
| -0.29% | -1.22% | +28.81% | +35.52% | 395B | |
| -0.35% | +1.90% | +25.12% | +3.11% | 340B | |
| -1.12% | -1.09% | +28.43% | +18.70% | 278B | |
| -0.45% | -1.48% | +20.24% | +24.41% | 254B | |
| +0.45% | +3.73% | -57.41% | -30.85% | 224B | |
| +0.11% | -3.68% | +17.41% | +16.70% | 171B | |
| -2.28% | -0.68% | +31.08% | +35.66% | 149B | |
| Average | -0.01% | +0.45% | +16.65% | +29.82% | 349.14B | |
| Weighted average by Cap. | +0.42% | +1.07% | +22.26% | +59.05% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 64.78B 55.19B 51.55B 48.5B 89.3B 5,868B 97.56B 602B 233B 2,766B 243B 238B 10,091B | 68.14B 58.05B 54.22B 51.02B 93.92B 6,172B 103B 633B 245B 2,909B 256B 250B 10,614B |
| Net income | 19.47B 16.59B 15.49B 14.58B 26.84B 1,763B 29.32B 181B 70.15B 831B 73.05B 71.51B 3,033B | 18.39B 15.67B 14.64B 13.77B 25.35B 1,666B 27.7B 171B 66.27B 785B 69.02B 67.56B 2,865B |
| Net Debt | 25.34B 21.59B 20.16B 18.97B 34.93B 2,295B 38.16B 235B 91.3B 1,082B 95.08B 93.07B 3,947B | 17.81B 15.18B 14.18B 13.34B 24.56B 1,614B 26.83B 165B 64.18B 761B 66.84B 65.43B 2,775B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-12 | 100.30 $ | +1.30% | 11,810,788 |
| 25-12-11 | 99.01 $ | +1.42% | 11,808,178 |
| 25-12-10 | 97.62 $ | +0.75% | 18,077,712 |
| 25-12-09 | 96.89 $ | -2.06% | 16,283,945 |
| 25-12-08 | 98.93 $ | -0.79% | 12,902,587 |
Delayed Quote Nyse, December 12, 2025 at 04:00 pm EST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- MRK Stock
Select your edition
All financial news and data tailored to specific country editions
